Epigenetic markers linked to PMDD across the menstrual cycle
Official title: Identification and Validation of Epigenetic Biomarkers of PMDD
Run by Johns Hopkins University · NCT06771583 · Data updated 2026-11-12
This study tests whether blood epigenetic markers can tell apart women with PMDD from women without PMDD at different points in the menstrual cycle.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 50 Years |
| Sex | Women only |
| Enrollment | 500 (estimated) |
| Sponsor | Johns Hopkins University Academic / other |
| Locations | 1 site (Baltimore, Maryland) |
| Status | Recruiting |
| Started | September 12, 2025 |
| Main results expected | February 15, 2030 |
| Study ends | February 15, 2031 |
| Registry record updated | May 7, 2026 |
| Trial ID | NCT06771583 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Women aged 18–50 with regular menstrual cycles who either have PMDD or do not have PMDD and who meet the study's medication and health criteria.
✕Probably not a fit
Women using steroid hormones or hormonal contraceptives, those with recent psychiatric medication or substance use disorders, recent pregnancy, uncontrolled endocrine disease, very high BMI, or recent major psychiatric illness are excluded and unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study collects blood samples and mood ratings from women with PMDD and from control women across the follicular and luteal phases of their menstrual cycles. Investigators will measure DNA methylation biomarkers previously linked to postpartum depression and use a repeated-measures approach to see if these markers vary by diagnosis and cycle phase. A secondary aim compares biomarkers between PMDD participants who have responded to SSRI treatment and those who have not. Eligible participants are women 18–50 with regular 24–35 day cycles who meet medication and health criteria.
Why it matters
Potential benefit: If validated, these biomarkers could enable a blood test to identify hormone sensitivity and help guide diagnosis and treatment choices for PMDD.
How similar studies have gone: The investigators previously reported an epigenetic biomarker that predicted postpartum depression with over 80% accuracy and a small cross-sectional PMDD cohort showed the biomarker distinguished cases from controls in the luteal phase.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * female sex * regular menstrual cycles (24-35 days) * age 18-50 years * ability to give written informed consent Exclusion Criteria: * psychiatric medication use in the past 2 months; * substance use disorder in the past 2 months (per MINI); * lifetime history of psychotic disorder including schizophrenia, schizoaffective disorder, major depression with psychotic features (per MINI); * history of psychiatric disorder other than PMDD in past year (per MINI); * active suicidal ideation with plan or attempt in past 6 months (per MINI); * steroid hormone or hormonal contraceptive use (except levonorgestrel as emergency contraceptive) in past 2 months; * pregnancy in past 6 months; * history of brain injury; * current or history of endocrine disorder including uncontrolled diabetes or thyroid disease; * BMI\>40.
Where it's running
-
Johns Hopkins Reproductive Mental Health Center
Baltimore, Maryland, United States Recruiting
Study contacts
- Principal investigator: Liisa Hantsoo, Ph.D. — Johns Hopkins University
- Study coordinator: Victoria Seo, B.S.
- Email: vseo1@jh.edu
- Phone: 302-464-8320
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Menstrual cycle symptoms and female health
This study will observe how common menstrual symptoms and related conditions appear in young adult women who have regular periods, to better understand their frequency and impact.
-
Moderate aerobic exercise to manage menstrual symptoms
This program will test whether a plan of moderate aerobic exercise can reduce physical and emotional menstrual symptoms in sedentary women who do or do not use hormonal birth control.
-
Kaia Relief - Cycle System for Premenstrual Symptoms in Premenopausal Women
This trial tests whether the Kaia Relief - Cycle System can help reduce premenstrual symptoms and menstrual discomfort in healthy women aged 18–45 over about 12 weeks.
-
How do occupational doctors handle PMDD in the workplace
This study tests what French occupational physicians know and how they think about PMDD and how they manage it in the workplace.
-
Pain and period life: does menstrual cycle or menopause change pain during root canals?
This study will see if pain during a root canal varies with menstrual cycle phase or menopausal status in adult patients.
-
Do PMDD patients have a different mid-luteal hormone balance than people without PMDD?
This study tests whether people with PMDD have different mid-luteal levels of progesterone and estradiol, and their ratio, compared with healthy controls.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.